EBPL Activators
EBPL Activators are a group of chemical compounds that enhance the activity of EBPL through various biochemical pathways and cellular processes. Phorbol 12-myristate 13-acetate (PMA) and Ionomycin enhance EBPL by activating protein kinase C and increasing intracellular calcium levels, respectively, which can lead to phosphorylation-dependent activation of EBPL. Similarly, Forskolin and 8-Bromo-cAMP raise intracellular cAMP levels, leading to the activation of PKA, which may phosphorylate and enhance EBPL activity. Compounds like Epidermal Growth Factor and Insulin trigger receptor-mediated signaling cascades that activate downstream kinases capable of enhancing EBPL activity through phosphorylation events.
Calyculin A and Okadaic acid prevent the dephosphorylation of proteins, potentially maintaining EBPL in an active phosphorylated state. BAY 11-7082 and LY294002 modulate activity by influencing NF-κB and PI3K pathways, respectively, which may resultin the indirect enhancement of EBPL if it is downstream of these pathways. U0126 and SB 203580 are inhibitors of key kinases within the MAPK/ERK and p38 MAPK pathways, respectively, and their use can lead to a reconfiguration of these signaling networks that may culminate in the enhanced activity of EBPL. These EBPL Activators collectively leverage the intrinsic regulatory mechanisms of phosphorylation, second-messenger signaling, and kinase/phosphatase interplay to enhance the function of EBPL.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diester of phorbol and is known to be a potent activator of protein kinase C (PKC). PKC activation can lead to phosphorylation of downstream proteins, enhancing the activity of EBPL through phosphorylation-dependent conformational changes. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can then phosphorylate target proteins, potentially enhancing EBPL activity if EBPL is a PKA substrate. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases, such as PKC, that could enhance the activity of EBPL by phosphorylation. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
Insulin binds to its receptor and activates the PI3K/Akt signaling pathway. Akt can phosphorylate various substrates that may interact with or modify EBPL activity. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $106.00 $166.00 $289.00 $550.00 $819.00 | 2 | |
This cAMP analog is resistant to degradation by phosphodiesterases and can activate PKA. Activated PKA can enhance the activity of EBPL through phosphorylation if EBPL is a substrate of PKA. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A sc-24000C | 10 µg 100 µg 1 mg | $160.00 $750.00 $3000.00 | 59 | |
Calyculin A is a serine/threonine phosphatase inhibitor. By inhibiting dephosphorylation, it can increase the phosphorylation state of proteins, including EBPL, if it is regulated by phosphorylation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is another potent inhibitor of protein phosphatases 1 and 2A, leading to increased phosphorylation and potential enhancement of EBPL activity if EBPL is regulated by such phosphatases. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 irreversibly inhibits NF-κB activation by blocking phosphorylation of IκBα, leading to modulation of proteins regulated by NF-κB, which could include EBPL if it is a target of NF-κB. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can increase the activity of certain proteins by inhibiting their negative regulation by PI3K. If EBPL is negatively regulated by a PI3K pathway, its activity could be enhanced. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 can lead to alterations in the activity of proteins in the p38 MAPK pathway, potentially enhancing EBPL if it is regulated by p38-dependent phosphorylation. | ||||||